VARIABLE BIOAVAILABILITY FOLLOWING REPEATED ORAL DOSES OF ETOPOSIDE

被引：64

作者：

HARVEY, VJ

SLEVIN, ML

JOEL, SP

SMYTHE, MM

JOHNSTON, A

WRIGLEY, PFM

机构：

[1] ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND

[2] HACKNEY HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON,ENGLAND

[3] ST BARTHOLOMEWS HOSP,DEPT CLIN PHARMACOL,LONDON EC1A 7BE,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1985年 / 21卷 / 11期

关键词：

D O I：

10.1016/0277-5379(85)90310-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1315 / 1319

页数：5

共 29 条

[1] COMPARISON OF HUMAN PHARMACOKINETICS OF VM-26 AND VP-16, 2 ANTINEOPLASTIC EPIPODOPHYLLOTOXIN GLUCOPYRANOSIDE DERIVATIVES
ALLEN, LM
CREAVEN, PJ
[J]. EUROPEAN JOURNAL OF CANCER, 1975, 11 (10) : 697 - 707
[2] ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71
[3] BEVERIDGE T, 1976, BIOAVAILABILITY STUD
[4] CAVALLI F, 1978, CANCER TREAT REP, V62, P473
[5] EFFECT OF POSTURE AND DRINK VOLUME ON THE SWALLOWING OF CAPSULES
CHANNER, KS
VIRJEE, J
[J]. BRITISH MEDICAL JOURNAL, 1982, 285 (6356) : 1702 - 1702
[6] SMALL CELL-CARCINOMA OF THE LUNG
COMIS, RL
[J]. CANCER TREATMENT REVIEWS, 1982, 9 (03) : 237 - 258
[7] CREAVEN PJ, 1975, CLIN PHARMACOL THER, V18, P221
[8] DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141
[9] DOMBERNOWSKY P, 1973, ACTA PATH MICRO IM A, VA 81, P715
[10] ETOPOSIDE AS SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY OF BRONCHOGENIC-CARCINOMA
GOLDHIRSCH, A
JOSS, R
CAVALLI, F
BRUNNER, KW
[J]. CANCER TREATMENT REVIEWS, 1982, 9 : 85 - 90